FDA
-
-
-
-
-
-
-
COGNITION Therapeutics receives patent notice for zervimesine to 2045
-
-
-
-
-
-
-
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
-
-
-
-
-
-
-
Cognition Therapeutics advances DLB psychosis program for zervimesine
-
-
-
-
-
-
-
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
-
-
-
-
-
-
-
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
-
-
-
-
-
-
-
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
-
329,987 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

